---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-007357"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2023-11-30T23:59:59+00:00"
generated_at: "2026-06-07T20:10:05.213675+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioCryst updates ORLADEYO Japan commercialization; new royalty tier at 80% above threshold

## Summary
- BioCryst Japan K.K. now handles all commercial promotion for ORLADEYO in Japan; Torii to conduct HAE disease awareness.
- Royalty amended: 20% on annual Japanese sales below a prespecified threshold, 80% on sales above that threshold.
- BioCryst assumes direct commercial activities for ORLADEYO in Japan via its subsidiary under updated Torii agreement.

## SEC filing metadata
- accession: 0001171843-23-007357
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2023-11-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184323007357/0001171843-23-007357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184323007357/f8k_113023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-007357
- JSON: https://secwatch.observer/filing/0001171843-23-007357.json
- Plain text: https://secwatch.observer/filing/0001171843-23-007357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.